NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $2.66 +0.04 (+1.53%) (As of 03:37 PM ET) Add Compare Share Share Today's Range$2.59▼$2.6850-Day Range$1.65▼$2.6652-Week Range$1.58▼$19.95Volume470,376 shsAverage Volume2.12 million shsMarket Capitalization$180.90 millionP/E RatioN/ADividend YieldN/APrice Target$17.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Amylyx Pharmaceuticals alerts: Email Address Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside561.7% Upside$17.60 Price TargetShort InterestHealthy3.61% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.73Based on 9 Articles This WeekInsider TradingAcquiring Shares$220,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.27) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector237th out of 927 stocksPharmaceutical Preparations Industry106th out of 425 stocks 3.1 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.61% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 24.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Read more about Amylyx Pharmaceuticals' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 2.6 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.27) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesSeptember 6, 2024 | insidertrades.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. Purchases 100,000 SharesSeptember 16 at 11:42 AM | globenewswire.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmSeptember 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 15 at 5:01 AM | americanbankingnews.comBrokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $17.60September 9, 2024 | finance.yahoo.comDirector Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)September 9, 2024 | seekingalpha.comAmylyx Pharmaceuticals: Management Ambitiously Navigates ChallengesSeptember 8, 2024 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. Buys 100,000 SharesSeptember 6, 2024 | finance.yahoo.comDirector MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)September 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.August 14, 2024 | markets.businessinsider.comCautious Optimism Amidst Uncertainty: Assessing Amylyx Pharmaceuticals’ Future ProspectsAugust 10, 2024 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | finance.yahoo.comWe Think Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Easily Afford To Drive Business GrowthAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough DesignationAugust 9, 2024 | seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | msn.comAmylyx Pharmaceuticals GAAP EPS of -$1.07August 8, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsJuly 18, 2024 | prnewswire.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmJuly 10, 2024 | benzinga.comWhy Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?See More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$17.60 High Stock Price Target$37.00 Low Stock Price Target$3.00 Potential Upside/Downside+571.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins-17.86% Pretax Margin-54.35% Return on Equity-15.51% Return on Assets-12.86% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$298.76 million Price / Sales0.60 Cash Flow$0.61 per share Price / Cash Flow4.29 Book Value$6.42 per share Price / Book0.41Miscellaneous Outstanding Shares68,006,000Free Float60,049,000Market Cap$178.18 million OptionableOptionable Beta-0.62 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Comp: $1.08MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Comp: $1.08MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Comp: $763.16kMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Comp: $689.26kDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Comp: $232.6kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GMMore ExecutivesKey CompetitorsMesoblastNASDAQ:MESOORIC PharmaceuticalsNASDAQ:ORICRapport TherapeuticsNASDAQ:RAPPProKidneyNASDAQ:PROKReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsGeorge M Milne JrBought 100,000 shares on 9/3/2024Total: $220,000.00 ($2.20/share)Maven Securities LTDBought 75,000 shares on 8/29/2024Ownership: 0.147%Almitas Capital LLCBought 1,903,851 shares on 8/16/2024Ownership: 2.800%Algert Global LLCBought 24,814 shares on 8/16/2024Ownership: 0.036%Point72 Asia Singapore Pte. Ltd.Bought 82,042 shares on 8/15/2024Ownership: 0.121%View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of the year. Since then, AMLX shares have decreased by 81.9% and is now trading at $2.66. View the best growth stocks for 2024 here. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its earnings results on Thursday, August, 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.35. The company had revenue of ($1.02) million for the quarter, compared to analysts' expectations of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative trailing twelve-month return on equity of 15.51%. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' top institutional investors include AQR Capital Management LLC (4.91%), Almitas Capital LLC (2.80%), Millennium Management LLC (2.26%) and Acadian Asset Management LLC (1.78%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, Global Investors Lp Viking, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.